SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-22-072281
Filing Date
2022-11-14
Accepted
2022-11-14 16:32:20
Documents
51
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0922_pasitheatherap.htm   iXBRL 10-Q 581688
2 EMPLOYMENT AGREEMENT WITH DANIEL SCHNEIDERMAN f10q0922ex10-1_pasithea.htm EX-10.1 89922
3 CERTIFICATION f10q0922ex31-1_pasithea.htm EX-31.1 10927
4 CERTIFICATION f10q0922ex31-2_pasithea.htm EX-31.2 11032
5 CERTIFICATION f10q0922ex32-1_pasithea.htm EX-32.1 5619
  Complete submission text file 0001213900-22-072281.txt   4000085

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ktta-20220930.xsd EX-101.SCH 39839
7 XBRL CALCULATION FILE ktta-20220930_cal.xml EX-101.CAL 24777
8 XBRL DEFINITION FILE ktta-20220930_def.xml EX-101.DEF 194836
9 XBRL LABEL FILE ktta-20220930_lab.xml EX-101.LAB 420350
10 XBRL PRESENTATION FILE ktta-20220930_pre.xml EX-101.PRE 207811
45 EXTRACTED XBRL INSTANCE DOCUMENT f10q0922_pasitheatherap_htm.xml XML 446255
Mailing Address 2110 NARCISSUS CT VENICE CA 90291
Business Address 2110 NARCISSUS CT VENICE CA 90291 8184226172
Pasithea Therapeutics Corp. (Filer) CIK: 0001841330 (see all company filings)

IRS No.: 851591963 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40804 | Film No.: 221386454
SIC: 2834 Pharmaceutical Preparations